1. Home
  2. CBIO vs BBBY Comparison

CBIO vs BBBY Comparison

Compare CBIO & BBBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$17.97

Market Cap

482.6M

Sector

N/A

ML Signal

N/A

BBBY

Bed Bath & Beyond Inc.

N/A

Current Price

$6.68

Market Cap

453.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CBIO
BBBY
Founded
2003
1971
Country
United States
United States
Employees
44
389
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
482.6M
453.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
BBBY
Price
$17.97
$6.68
Analyst Decision
Strong Buy
Hold
Analyst Count
6
3
Target Price
$26.67
$8.00
AVG Volume (30 Days)
240.6K
2.5M
Earning Date
04-29-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$6.35
Revenue Next Year
$279.20
$7.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.72
$4.26
52 Week High
$27.41
$12.65

Technical Indicators

Market Signals
Indicator
CBIO
BBBY
Relative Strength Index (RSI) 43.06 64.36
Support Level $17.02 $4.51
Resistance Level $19.05 $7.71
Average True Range (ATR) 1.20 0.50
MACD -0.06 0.05
Stochastic Oscillator 27.11 99.03

Price Performance

Historical Comparison
CBIO
BBBY

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About BBBY Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc is an e-commerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering products and services that enable its customers to enhance everyday life through quality, style, and value. The company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites, as well as a blockchain asset portfolio. Its e-commerce platforms, www.bedbathandbeyond.com and www.overstock.com, are targeted at customers seeking various products such as furniture, bedding, area rugs, tabletop and cookware, decor, storage, jewelry, etc, at affordable prices. In addition to products, the company also offers add-on services across platforms, including warranties, shipping insurance, and installation services.

Share on Social Networks: